Shanghai Celgen To Buy Back Simcere's 35% Stake For $48.1 Million
19:24 EST 23 Jan 2013 | Elsevier Business Intelligence
Shanghai Celgen Bio-Pharmaceutical is about to buy back from Simcere Pharmaceutical Group all of its shares for $48.1 million in an all-China deal.
Original Article: Shanghai Celgen To Buy Back Simcere's 35% Stake For $48.1 Million
More From BioPortfolio on "Shanghai Celgen To Buy Back Simcere's 35% Stake For $48.1 Million"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
